Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M J Millan

Showing results (221-230 of 224) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 224 results.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profileM J Millan, A Gobert, A Newman-Tancredi, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 20, 2016
Deconstructing vulnerability for psychosis: Meta-analysis of environmental risk factors for psychosis in subjects at ultra high-riskP Fusar-Poli, M Tantardini, S De Simone, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidineM J Millan, A Dekeyne, A Newman-Tancredi, et al.
Scientific Reports|August 16, 2019
The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cellsM Jacoupy, E Hamon-Keromen, A Ordureau, et al.
Pageof 23

Showing results (221-230 of 224) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 224 results.
The Journal of Pharmacology and Experimental Therapeutics|December 22, 1999
S18327 (1-[2-[4-(6-fluoro-1, 2-benzisoxazol-3-yl)piperid-1-yl]ethyl]3-phenyl imidazolin-2-one), a novel, potential antipsychotic displaying marked antagonist properties at alpha(1)- and alpha(2)-adrenergic receptors: I. Receptorial, neurochemical, and electrophysiological profileM J Millan, A Gobert, A Newman-Tancredi, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|December 20, 2016
Deconstructing vulnerability for psychosis: Meta-analysis of environmental risk factors for psychosis in subjects at ultra high-riskP Fusar-Poli, M Tantardini, S De Simone, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 18, 2000
S18616, a highly potent, spiroimidazoline agonist at alpha(2)-adrenoceptors: I. Receptor profile, antinociceptive and hypothermic actions in comparison with dexmedetomidine and clonidineM J Millan, A Dekeyne, A Newman-Tancredi, et al.
Scientific Reports|August 16, 2019
The PINK1 kinase-driven ubiquitin ligase Parkin promotes mitochondrial protein import through the presequence pathway in living cellsM Jacoupy, E Hamon-Keromen, A Ordureau, et al.
Pageof 23